Regencell Bioscience Holdings (Regencell Bioscience Holdings) Debt-to-Asset : 0.04 (As of Jun. 2023)

View and export this data going back to 2021. Start your Free Trial

What is Regencell Bioscience Holdings Debt-to-Asset?

Regencell Bioscience Holdings's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Jun. 2023 was $0.44 Mil. Regencell Bioscience Holdings's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Jun. 2023 was $0.03 Mil. Regencell Bioscience Holdings's Long-Term Debt & Capital Lease ObligationTotal Assets for the quarter that ended in Jun. 2023 was $12.62 Mil. Regencell Bioscience Holdings's debt to asset for the quarter that ended in Jun. 2023 was 0.04.

Regencell Bioscience Holdings Debt-to-Asset Historical Data

The historical data trend for Regencell Bioscience Holdings's Debt-to-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Regencell Bioscience Holdings Debt-to-Asset Chart

Regencell Bioscience Holdings Annual Data

Trend

Jun19

Jun20

Jun21

Jun22

Jun23

Debt-to-Asset

8.57

5.97

10.83

0.04

Regencell Bioscience Holdings Semi-Annual Data
	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23
Debt-to-Asset	Get a 7-Day Free Trial				10.83	-	0.04	-	0.04

Competitive Comparison of Regencell Bioscience Holdings's Debt-to-Asset

For the Drug Manufacturers - Specialty & Generic subindustry, Regencell Bioscience Holdings's Debt-to-Asset, along with its competitors' market caps and Debt-to-Asset data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Regencell Bioscience Holdings's Debt-to-Asset Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Regencell Bioscience Holdings's Debt-to-Asset distribution charts can be found below:

* The bar in red indicates where Regencell Bioscience Holdings's Debt-to-Asset falls into.

Regencell Bioscience Holdings Debt-to-Asset Calculation

Debt to Asset measures the financial leverage a company has.

Regencell Bioscience Holdings's Debt-to-Asset for the fiscal year that ended in Jun. 2023 is calculated as

Debt-to-Asset	=	Total Debt			/	Total Assets
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Assets
	=	(0.438	+	0.025)	/	12.622
	=	0.04

Regencell Bioscience Holdings's Debt-to-Asset for the quarter that ended in Jun. 2023 is calculated as

Debt-to-Asset	=	Total Debt			/	Total Assets
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Assets
	=	(0.438	+	0.025)	/	12.622
	=	0.04

Regencell Bioscience Holdings (NAS:RGC) Debt-to-Asset Explanation

In the calculation of Debt-to-Asset, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by Total Assets.

Regencell Bioscience Holdings Debt-to-Asset Related Terms

Thank you for viewing the detailed overview of Regencell Bioscience Holdings's Debt-to-Asset provided by GuruFocus.com. Please click on the following links to see related term pages.

Regencell Bioscience Holdings (Regencell Bioscience Holdings) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Regencell Bioscience Holdings Ltd (NAS:RGC) » Definitions » Debt-to-Asset

Comparable Companies

Traded in Other Exchanges

N/A

Address

29 Leighton Road, 9/F Chinachem Leighton Plaza, Causeway Bay, Hong Kong, HKG

Website

https://www.regencellbioscience.com

Regencell Bioscience Holdings Ltd is engaged in the research, development and commercialization of traditional Chinese medicine. The medicines are used for the treatment of neurocognitive disorders and degeneration.